scout
|Videos|May 22, 2017

Results for HS-410 Vaccine in Non-Muscle Invasive Bladder Cancer

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME